Advertisement
U.S. Markets closed

Lytix Biopharma AS (LYTIX.OL)

Oslo - Oslo Delayed Price. Currency in NOK
6.00-0.10 (-1.64%)
At close: 04:25PM CEST
Currency in NOK

Valuation Measures4

Market Cap (intraday) 302.62M
Enterprise Value 245.44M
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm)17.93
Price/Book (mrq)5.11
Enterprise Value/Revenue 16.99
Enterprise Value/EBITDA -2.06

Trading Information

Stock Price History

Beta (5Y Monthly) -0.52
52-Week Change 3N/A
S&P500 52-Week Change 3N/A
52 Week High 315.00
52 Week Low 34.60
50-Day Moving Average 38.36
200-Day Moving Average 37.39

Share Statistics

Avg Vol (3 month) 3103.16k
Avg Vol (10 day) 353.4k
Shares Outstanding 549.61M
Implied Shares Outstanding 6N/A
Float 825.02M
% Held by Insiders 141.74%
% Held by Institutions 10.00%
Shares Short 4N/A
Short Ratio 4N/A
Short % of Float 4N/A
Short % of Shares Outstanding 4N/A
Shares Short (prior month ) 4N/A

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 30.00
Trailing Annual Dividend Yield 30.00%
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2023
Most Recent Quarter (mrq)Jun 30, 2024

Profitability

Profit Margin 0.00%
Operating Margin (ttm)-543.01%

Management Effectiveness

Return on Assets (ttm)-53.28%
Return on Equity (ttm)-105.16%

Income Statement

Revenue (ttm)14.44M
Revenue Per Share (ttm)0.34
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)N/A
EBITDA -78.36M
Net Income Avi to Common (ttm)-76.42M
Diluted EPS (ttm)-1.79
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)60.18M
Total Cash Per Share (mrq)1.21
Total Debt (mrq)3M
Total Debt/Equity (mrq)5.06
Current Ratio (mrq)4.61
Book Value Per Share (mrq)1.19

Cash Flow Statement

Operating Cash Flow (ttm)-87.16M
Levered Free Cash Flow (ttm)-58.68M